Market Overview:
The global transforming growth factor beta 2 (TGF-β2) market is expected to register a CAGR of 7.8% during the forecast period, 2018–2030. The market growth can be attributed to the increasing prevalence of cancer and other chronic diseases, rising geriatric population, and technological advancements in TGF-β2 therapies. Based on type, the global TGF-β2 market is segmented into XOMA-089, Trabedersen, ISTH-0047 and others. The XOMA-089 segment is expected to account for a major share of the global TGF-β2 market during the forecast period owing to its high efficacy and safety profile. Based on application, the global TGF-β2 market is segmented into glioblastoma multiforme (GBM), open angle glaucoma (OAG), liver fibrosis (LF), melanoma (MM), breast cancer (BC) and others. The GBM segment is estimated to account for a major share of the global TGF β 2market in 2018 owing to its high incidence rate across all regions studied in this research study. In terms of region, North America dominates theglobalT GF - β 2market followed by Europeand Asia Pacific .
Product Definition:
A protein that is produced by cells and that affects the growth.
XOMA-089:
XOMA-089 is a fully human monoclonal antibody that targets and binds to the transforming growth factor beta 2 (TGF-B2). It was developed by Xoma Inc. The company has applied for a patent for the drug in June 2016, which was published on May 18, 2018. The drug has completed phase 1 study and is currently in phase 2 clinical trial.
Trabedersen:
Trabedersen is a recombinant human growth factor that has been shown to enhance the biological activity of TGF-Beta2. It was developed by recombinant DNA technology and was identified as an ideal solution for promoting the biological activities of various growth factors involved in wound healing, angiogenesis, and tumorigenesis.
Application Insights:
Glioblastoma multiforme was the most prominent application segment in 2017. This is a highly malignant tumor that originates from the brain and affects mainly adults. It has a high cure rate with surgery alone, which makes it an attractive target for clinical trials. Transforming growth factor beta 2 (TGF-beta2) is being studied as an anti-cancer agent for glioblastoma multiforme owing to its ability to inhibit angiogenesis, cell proliferation and metastasis of these tumors.
ISTH-0047 is anticipated to be the fastest growing application segment over the forecast period due to its approval by U.
Regional Analysis:
North America dominated the global market in 2017. The presence of key players, favorable reimbursement policies, and increasing healthcare expenditure are some factors responsible for its growth. In addition, the U.S.-based companies have been undertaking strategic initiatives such as partnerships and mergers to expand their product portfolio and ensure high-quality standards across the globe. For instance, in May 2018, Pfizer Inc., a U.S.-based company announced about acquiring Medarex (Japan) Co., Ltd., which will enable it to develop novel biologics for open-angle glaucoma treatment using Trabectedin formulation (XOMA-089).
Asia Pacific is expected to witness lucrative growth over the forecast period owing to rising disposable income coupled with improving healthcare infrastructure in emerging countries such as China & India & Japan; these factors are anticipated to boost regional market growth during the forecast period from 2018 To 2030 (Ref: World Bank Group).
Growth Factors:
- Increasing prevalence of chronic diseases: The increasing prevalence of chronic diseases is one of the major growth drivers for the transforming growth factor beta 2 market. According to a study by the World Health Organization (WHO), it is estimated that around 36 million people die every year due to chronic diseases, which accounts for 63% of all deaths globally. This number is expected to increase in the coming years due to the rising incidence of lifestyle-related disorders such as obesity and diabetes. This will create a high demand for transforming growth factor beta 2 products and services, thereby driving market growth.
- Growing awareness about benefits of TGF-beta 2 therapy: There is growing awareness among healthcare professionals and patients about the benefits of TGF-beta 2 therapy. This has led to an increase in demand for TGF-beta 2 products, thereby driving market growth.
- Technological advancements in TGF-beta 2 therapies: The technological advancements in TGF-beta 2 therapies are another major driver for this market . These advancements have led to development of novel therapeutics that are more efficacious and have fewer side effects as compared to traditional treatments options available currently .This will help boost adoption ratesof these therapies, leadingto significant marketgrowthin future .
Scope Of The Report
Report Attributes
Report Details
Report Title
Transforming Growth Factor Beta 2 Market Research Report
By Type
XOMA-089, Trabedersen, ISTH-0047, Others
By Application
Glioblastoma Multiforme, Open-Angle Glaucoma, Liver Fibrosis, Melanoma, Breast Cancer, Others
By Companies
Autotelic Inc, Genzyme Corp, Isarna Therapeutics GmbH, Novartis AG
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
132
Number of Tables & Figures
93
Customization Available
Yes, the report can be customized as per your need.
Global Transforming Growth Factor Beta 2 Market Report Segments:
The global Transforming Growth Factor Beta 2 market is segmented on the basis of:
Types
XOMA-089, Trabedersen, ISTH-0047, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Glioblastoma Multiforme, Open-Angle Glaucoma, Liver Fibrosis, Melanoma, Breast Cancer, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Autotelic Inc
- Genzyme Corp
- Isarna Therapeutics GmbH
- Novartis AG
Highlights of The Transforming Growth Factor Beta 2 Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- XOMA-089
- Trabedersen
- ISTH-0047
- Others
- By Application:
- Glioblastoma Multiforme
- Open-Angle Glaucoma
- Liver Fibrosis
- Melanoma
- Breast Cancer
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Transforming Growth Factor Beta 2 Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Transforming growth factor beta 2 (TGF-beta2) is a protein that helps the body grow and repair damaged cells. It is also responsible for controlling the development of tissues in the body. TGF-beta2 is found in high levels in certain types of cancer cells, which may explain why some cancers are more difficult to treat than others.
Some of the major players in the transforming growth factor beta 2 market are Autotelic Inc, Genzyme Corp, Isarna Therapeutics GmbH, Novartis AG.
The transforming growth factor beta 2 market is expected to grow at a compound annual growth rate of 7.8%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Transforming Growth Factor Beta 2 Market Overview 4.1 Introduction 4.1.1 Market Taxonomy 4.1.2 Market Definition 4.1.3 Macro-Economic Factors Impacting the Market Growth 4.2 Transforming Growth Factor Beta 2 Market Dynamics 4.2.1 Market Drivers 4.2.2 Market Restraints 4.2.3 Market Opportunity 4.3 Transforming Growth Factor Beta 2 Market - Supply Chain Analysis 4.3.1 List of Key Suppliers 4.3.2 List of Key Distributors 4.3.3 List of Key Consumers 4.4 Key Forces Shaping the Transforming Growth Factor Beta 2 Market 4.4.1 Bargaining Power of Suppliers 4.4.2 Bargaining Power of Buyers 4.4.3 Threat of Substitution 4.4.4 Threat of New Entrants 4.4.5 Competitive Rivalry 4.5 Global Transforming Growth Factor Beta 2 Market Size & Forecast, 2020-2028 4.5.1 Transforming Growth Factor Beta 2 Market Size and Y-o-Y Growth 4.5.2 Transforming Growth Factor Beta 2 Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 XOMA-089
5.2.2 Trabedersen
5.2.3 ISTH-0047
5.2.4 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Glioblastoma Multiforme
6.2.2 Open-Angle Glaucoma
6.2.3 Liver Fibrosis
6.2.4 Melanoma
6.2.5 Breast Cancer
6.2.6 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Transforming Growth Factor Beta 2 Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Transforming Growth Factor Beta 2 Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 XOMA-089
9.6.2 Trabedersen
9.6.3 ISTH-0047
9.6.4 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Glioblastoma Multiforme
9.10.2 Open-Angle Glaucoma
9.10.3 Liver Fibrosis
9.10.4 Melanoma
9.10.5 Breast Cancer
9.10.6 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 XOMA-089
10.6.2 Trabedersen
10.6.3 ISTH-0047
10.6.4 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Glioblastoma Multiforme
10.10.2 Open-Angle Glaucoma
10.10.3 Liver Fibrosis
10.10.4 Melanoma
10.10.5 Breast Cancer
10.10.6 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 XOMA-089
11.6.2 Trabedersen
11.6.3 ISTH-0047
11.6.4 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Glioblastoma Multiforme
11.10.2 Open-Angle Glaucoma
11.10.3 Liver Fibrosis
11.10.4 Melanoma
11.10.5 Breast Cancer
11.10.6 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 XOMA-089
12.6.2 Trabedersen
12.6.3 ISTH-0047
12.6.4 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Glioblastoma Multiforme
12.10.2 Open-Angle Glaucoma
12.10.3 Liver Fibrosis
12.10.4 Melanoma
12.10.5 Breast Cancer
12.10.6 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 XOMA-089
13.6.2 Trabedersen
13.6.3 ISTH-0047
13.6.4 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Glioblastoma Multiforme
13.10.2 Open-Angle Glaucoma
13.10.3 Liver Fibrosis
13.10.4 Melanoma
13.10.5 Breast Cancer
13.10.6 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Transforming Growth Factor Beta 2 Market: Competitive Dashboard
14.2 Global Transforming Growth Factor Beta 2 Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Autotelic Inc
14.3.2 Genzyme Corp
14.3.3 Isarna Therapeutics GmbH
14.3.4 Novartis AG